0001181431-11-048283.txt : 20110907 0001181431-11-048283.hdr.sgml : 20110907 20110907075417 ACCESSION NUMBER: 0001181431-11-048283 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110901 FILED AS OF DATE: 20110907 DATE AS OF CHANGE: 20110907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Johnston David Brannon CENTRAL INDEX KEY: 0001486519 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34655 FILM NUMBER: 111077103 MAIL ADDRESS: STREET 1: AVEO PHARMACEUTICALS, INC. STREET 2: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001325879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 SIDNEY STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172995000 MAIL ADDRESS: STREET 1: 75 SIDNEY STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 rrd321415.xml X0304 4 2011-09-01 0 0001325879 AVEO PHARMACEUTICALS INC AVEO 0001486519 Johnston David Brannon C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Common Stock 2011-09-01 4 M 0 2000 5.60 A 8000 D Common Stock 2011-09-01 4 S 0 2000 16.8735 D 6000 D Employye Stock Option (right-to-buy) 5.60 2011-09-01 4 M 0 2000 0 D 2017-10-31 Common Stock 2000 170000 D The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2011. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.67 to $16.97, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. The option vested as to 25% of the shares on October 31, 2008 and as to an additional 1/48 of the shares per month thereafter. /s/ Joseph D. Vittiglio, Esq., attorney-in-fact 2011-09-06